secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092712
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis Q2 revenue $22.6M (+35% YoY); raises FY 2024 revenue guidance to $79-81M
--------------------------------------------------------------------------------

- Total revenue $22.6M, up 35% YoY; pharma testing $13.2M (+117% YoY).
- Net loss $12.8M, improved from $24.0M loss in Q2 2023; cash $87.0M.
- FY 2024 revenue guidance raised to $79-81M from $76-78M; non-GAAP net loss ~$75M.
- Cross-license agreement with Myriad Genetics; settled IP lawsuit with Foresight Diagnostics.
- Delivered 561 molecular tests in Q2, up 66% QoQ; launched NeXT Personal Dx with Tempus AI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000095017024092712/0000950170-24-092712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000095017024092712/psnl-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer